Kidney Effects of Finerenone Added to Sodium‐Glucose Cotransporter 2 Inhibitors in Patients With Diabetic Kidney Disease
Qing Yang, Lijun Zhao, J F Ma, Shuming Ji, Duolao Wang, Jing Li, Sheyu Li, Fang Liu
West China Medical Center of Sichuan University West China Hospital of Sichuan University Sichuan University Liverpool School of Tropical Medicine
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Background Both finerenone and sodium‐glucose cotransporter 2 inhibitors (SGLT‐2Is) improve kidney outcomes in people with type 2 diabetes (T2D) and chronic kidney disease (CKD), but the real‐world effectiveness of their combination remains unclear. Methods This retrospective, single‐center study recruited people with T2D‐CKD receiving finerenone on SGLT‐2Is or SGLT‐2Is alone in West China Hospital of Sichuan University. Kidney outcomes were compared after 1:4 propensity score matching. The primary outcome was the time from drug initiation to ≥ 30% decline in eGFR. The secondary outcome was the change in chronic eGFR slope. Results The matched cohort included 228 SGLT‐2Is initiators and 69 finerenone initiators on SGLT‐2Is. The baseline mean age was 54.5 years, with eGFR of 68.8 mL/min/1.73 m 2 and eGFR slope of −2.1 mL/min/1.73 m 2 /year. Over a median follow‐up of 18.1 months, people receiving finerenone and SGLT‐2Is were associated with a reduced risk of ≥ 30% eGFR decline (HR: 0.26; 95% CI: 0.11–0.57) compared to those who received SGLT‐2Is only. The between‐group difference in post‐treatment chronic eGFR slope was −0.74 mL/min/1.73 m 2 /year (95% CI: −2.95–1.45). However, of those with rapid pre‐treatment eGFR decline, the finerenone on SGLT‐2Is group experienced significantly greater eGFR decline compared to the SGLT‐2Is group (mean difference: −6.28 mL/min/1.73 m 2 /year; 95% CI: −11.81 to −0.75). Conclusion Finerenone added to SGLT‐2Is was associated with slower eGFR decline in most individuals with T2D‐CKD. However, people with rapid pre‐treatment eGFR decline may experience accelerated deterioration when finerenone is added. These findings are hypothesis‐generating rather than confirmatory, requiring further well‐designed and prospective studies for validation.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Chronic Kidney Disease and Diabetes
Diabetes Treatment and Management · Acute Kidney Injury Research